Key result
Intracoronary enalaprilat reduced the fractional conversion of Angiotensin I to Angiotensin II by 89% in the intact human heart, demonstrating that the predominant pathway for Angiotensin II formation is through ACE.
Why the study?
Does enalaprilat reduce angiotensin II formation in the intact human heart?
Does enalaprilat reduce angiotensin II formation in the intact human heart?
Effect estimate: 89% reduction
Absolute Event Rate: 0.044% vs 0.415%
p-value: p=0.002
The predominant pathway for angiotensin II formation in the human heart is through the angiotensin-converting enzyme (ACE), contrary to previous proposals suggesting non-ACE pathways predominate.
No takes yet. Share an insight, caveat, or question.
ACE predominates cardiac Ang II formation; leaves open whether this extends to native failing hearts or alters ACEI dosing.
Zisman et al. (1995) studied Heart transplant recipients and heart failure (n=20). Intracoronary enalaprilat vs. Baseline (without enalaprilat) was evaluated on Fractional conversion of Angiotensin I to Angiotensin II (89% reduction, p=0.002). Intracoronary enalaprilat reduced the fractional conversion of Angiotensin I to Angiotensin II by 89% in the intact human heart, demonstrating that the predominant pathway for Angiotensin II formation is through ACE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: